Evidence map›Paper›PMID 30303036›Full record

ReviewMultiple sclerosis (Houndmills, Basingstoke, England)2018

Recommendations for cognitive screening and management in multiple sclerosis care.

Rosalind Kalb, Meghan Beier, Ralph Hb Benedict, Leigh Charvet, Kathleen Costello, Anthony Feinstein, Jeffrey Gingold, Yael Goverover, June Halper, Colleen Harris and 6 more

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Multiple sclerosis (Houndmills, Basingstoke, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04153773 (Retinal Thickness as a Potential Biomarker of Neurodegeneration and Early Cognitive Impairment in Patients With Multiple Sclerosis), which is not on this map. Cited by 170 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed, 8 pooled it
21.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04153773 completednot on this map

Retinal Thickness as a Potential Biomarker of Neurodegeneration and Early Cognitive Impairment in Patients With Multiple Sclerosis

TypeobservationalSponsorMansoura University HospitalRan2018 to 2019Enrolled90ConditionsMultiple SclerosisArmsOCT
3 · Its place in the literature

Who cites it

170 citing papers in PubMed, 8 syntheses or guidelines pooled it, 394 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. A cluster-randomised controlled feasibility trial evaluating the Cognitive Occupation-Based programme for people with Multiple Sclerosis (COB-MS).Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Trial
  13. Trial
  14. Trial
  15. Review
  16. Article
  17. Article
  18. Exploring the relationship between retinal damage and cognition in multiple sclerosis: a cross-sectional OCT-MRI study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  19. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026
    Article
  20. Review

110 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 2 countries.

Rosalind KalbNational Multiple Sclerosis Society, New York, NY, USA.
Meghan BeierDivision of Rehabilitation Psychology and Neuropsychology, Department of Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ralph Hb BenedictDepartment of Neurology, University at Buffalo, Buffalo, NY, USA.
Leigh CharvetDepartment of Neurology, Langone Medical Center, New York University, New York, NY, USA.
Kathleen CostelloNational Multiple Sclerosis Society, New York, NY, USA.
Anthony FeinsteinDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada.
Jeffrey GingoldNational Multiple Sclerosis Society, New York, NY, USA.
Yael GoveroverNew York University, New York, NY, USA.
June HalperThe Consortium of Multiple Sclerosis Centers and International Organization of Multiple Sclerosis Nurses, Multiple Sclerosis Nurses International Certification Board, Hackensack, NJ, USA.
Colleen HarrisMultiple Sclerosis Center, University of Calgary, Calgary, AB, Canada.
Lori KostichThe Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Hartford, CT, USA.
Lauren KruppDepartment of Neurology, NYU Langone Health, New York University, New York, NY, USA.
Ellen LathiThe Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA, USA.
Nicholas LaRoccaNational Multiple Sclerosis Society, New York, NY, USA.
Ben ThrowerEmory University, Atlanta, GA, USA/Andrew C. Carlos Multiple Sclerosis Institute at Shepherd Center, Atlanta, GA, USA.
John DeLucaDepartment of Physical Medicine and Rehabilitation and Department of Neurology, Rutgers New Jersey Medical School, Newark, NJ, USA.
National Multiple Sclerosis Society · USNYU Langone Health · USHartford Financial Services (United States)Johns Hopkins University · USMultiple Sclerosis Center Of Northeastern New York · USMultiple Sclerosis Foundation · USNew York University · USRutgers New Jersey Medical SchoolShepherd Center · USUniversity at Buffalo, State University of New York · USUniversity of Calgary · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo promote understanding of cognitive impairment in multiple sclerosis (MS), recommend optimal screening, monitoring, and treatment strategies, and address barriers to optimal management.

methodsThe National MS Society ("Society") convened experts in cognitive dysfunction (clinicians, researchers, and lay people with MS) to review the published literature, reach consensus on optimal strategies for screening, monitoring, and treating cognitive changes, and propose strategies to address barriers to optimal care. RECOMMENDATIONS: Based on current evidence, the Society makes the following recommendations, endorsed by the Consortium of Multiple Sclerosis Centers and the International Multiple Sclerosis Cognition Society: Increased professional and patient awareness/education about the prevalence, impact, and appropriate management of cognitive symptoms. For adults and children (8+ years of age) with clinical or magnetic resonance imaging (MRI) evidence of neurologic damage consistent with MS: As a minimum, early baseline screening with the Symbol Digit Modalities Test (SDMT) or similarly validated test, when the patient is clinically stable; Annual re-assessment with the same instrument, or more often as needed to (1) detect acute disease activity; (2) assess for treatment effects (e.g. starting/changing a disease-modifying therapy) or for relapse recovery; (3) evaluate progression of cognitive impairment; and/or (4) screen for new-onset cognitive problems. For adults (18+ years): more comprehensive assessment for anyone who tests positive on initial cognitive screening or demonstrates significant cognitive decline, especially if there are concerns about comorbidities or the individual is applying for disability due to cognitive impairment. For children (<18 years): neuropsychological evaluation for any unexplained change in school functioning (academic or behavioral). Remedial interventions/accommodations for adults and children to improve functioning at home, work, or school.

Indexed as

CognitionCognition DisordersCognitive DysfunctionHumansMass ScreeningMultiple SclerosisNeuropsychological Testscognitioncognitive dysfunctionMultiple sclerosisrehabilitationremediationscreeningtreatment

Identifiers

PMID30303036
PMCPMC6238181
OpenAlexW2895845951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.